Key Drivers
- Strong margins
- Heavy leverage
- Negative cash flow
AIAI Summary
IBRX has shifted from a pure pipeline bet to a real commercial story thanks to ANKTIVA's rapid revenue growth and strong gross margins, but the investment case still depends on sales scaling fast enough to outrun heavy losses, rising debt, and litigation/FDA overhangs before valuation gets ahead of fundamentals.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong margins
- •Heavy leverage
- •Negative cash flow
IBRX has strong gross margins and liquidity, but persistent operating losses, negative free cash flow, rising debt, and deeply negative equity make the stock fundamentally risky.
Price Behavior
Key Price Behavior Insights:
- •Range-bound action
- •Rebound buying
- •Resistance capped
IBRX was mostly range-bound to slightly weak over the last month, bouncing off $6.83-$6.95 support but still capped by $7.65-$7.88 resistance, so a clean move above that zone is needed to confirm stronger momentum. ക
Strong rebound from $6.83-$6.95 lows after weakness
Sentiment & News
Key News Insights:
- •Record revenue
- •UAE expansion
- •Pipeline catalysts
ImmunityBio's latest updates show ANKTIVA driving rapid revenue growth, new UAE authorization expanding its reach, and a growing pipeline/corporate backdrop that supports a constructive long-term outlook.
The news is broadly positive for IBRX, as accelerating ANKTIVA commercialization and new regulatory wins strengthen near-term growth while pipeline progress supports longer-term upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings